Generic Name and Formulations:
Sargramostim (recombinant human granulocyte-macrophage colony stimulating factor, or rhu GM-CSF) 250mcg; per vial; pwd for SC inj or IV infusion after reconstitution; preservative-free.
Sanofi Genzyme Company
Indications for LEUKINE:
To speed neutrophil recovery and reduce infections after induction chemotherapy in treatment of acute myelogenous leukemia (AML) in patients >55 years of age. To mobilize hematopoietic progenitor cells into peripheral blood for collection by leukapheresis. To speed myeloid recovery in non-Hodgkin's lymphoma, acute lymphoblastic leukemia (ALL), and Hodgkin's disease in autologous bone marrow transplantation (BMT). To speed myeloid recovery in allogeneic BMT. Patients with BMT failure or engraftment delay.
See full labeling for timing and duration of dosing, and for repeat courses of therapy. Individualize. Neutrophil recovery: 250mcg/m2 per day IV over 4 hrs. Mobilization or post peripheral blood progenitor cell transplantation: 250mcg/m2 per day IV over 24 hrs or SC once daily. Myeloid recovery after BMT: 250mcg/m2 per day IV over 2 hrs. BMT failure or engraftment delay: 250mcg/m2 per day IV over 2 hrs for 14 days.
See full labeling.
Excessive leukemic myeloid blasts in bone marrow or peripheral blood (≥10%). Allergy to GM-CMF or yeast-derived products. Concomitant (within 24 hrs) chemotherapy or radiotherapy.
Fluid retention, pleural or pericardial effusions. Pulmonary infiltrates. Respiratory disease or symptoms. Hypoxia. Reduce infusion rate by ½ if dyspnea occurs; discontinue if dyspnea worsens. Cardiac disease. CHF. Renal or hepatic dysfunction (monitor before and every other week during therapy). Monitor CBC and differential twice weekly. Reduce dose by ½ or discontinue if absolute neutrophil count exceeds 20,000cells/mm3 or if platelet count exceeds 500,000cells/mm3. Use for shortest duration required. Myeloid malignancies. Monitor body weight and hydration. Pregnancy (Cat.C). Nursing mothers.
Caution with lithium, corticosteroids, others that may enhance myeloproliferative effects. May be antagonized by radiotherapy, myelotoxic drugs.
Granulocyte-macrophage colony stimulating factor (recombinant).
Flu-like symptoms, GI disturbances, edema, dyspnea, pharyngitis, rash, joint or bone or chest pain, eye hemorrhage, hypomagnesemia, anxiety, headache, pleural +/or pericardial effusion, arthralgia, myalgia, others.
Endocrinology Advisor Articles
- ACP Defends Higher Blood Glucose Targets for Type 2 Diabetes
- Updated Clinical Practice Guidelines on Testosterone Therapy in Men With Hypogonadism
- Semaglutide May Be Useful for Treating Obesity in People Without Diabetes
- Once-Daily Oral Contraceptive for Men Shows Promise
- HbA1c Levels Affect Serum Phospholipids, Inflammation inT2D, CVD
- American College of Physicians Releases 4 Guidelines for HbA1c Targets in T2D
- Dyslipidemia Drug Indications
- No Difference in Weight Loss Outcomes With Low-Fat vs Low-Carbohydrate Diet
- Damaging Effects of Gastric Bypass Surgery on Bone Mass and Microarchitecture
- Gastric Bypass Surgery Linked to Increased Risk for Nonvertebral Fractures
- Common Plant-Derived Oils May Contain Endocrine-Disrupting Chemicals
- Red Meat Consumption Linked to Insulin Resistance and Steatohepatitis
- Effect of High Androgen Levels on Cardiovascular Risk in Postmenopausal Women
- Fertility in Women Negatively Affected by Asthma Medications
- Glucocorticoid Use in COPD Does Not Increase Fracture Risk